In mice engrafted with CD19+ Raji lymphoma cells, those infused with CD19-directed CAR T-cells rapidly developed CRS, and administration of dasatinib significantly decreased levels of IFN-γ, GM-CSF, IL-2, and TNF-α and protected mice from fatal CRS. This evidence concerns the gene CSF2 and lymphoma.